문합기 시장 : 제품 유형, 기술, 수술 유형, 재료 유형, 사용 방법, 유통 채널, 용도, 최종 용도별 - 세계 예측(2026-2032년)

The Anastomosis Devices Market is projected to grow by USD 5.71 billion at a CAGR of 8.38% by 2032.

The anastomosis devices market is expanding as hospitals prioritize faster, more consistent tissue and vessel connection in gastrointestinal, colorectal, bariatric, thoracic, cardiovascular, and transplant surgery. Demand is supported by the global shift toward minimally invasive surgery, higher procedure volumes tied to aging populations, and clinical pressure to reduce anastomotic leak, bleeding, stricture, and operating-room time.

Validated technologies such as circular staplers, linear staplers, compression anastomosis systems, vascular anastomosis devices, automated suturing platforms, and adjunctive sealants are being evaluated against outcomes that matter to payers and providers: leak rates, length of stay, readmission, surgeon ergonomics, and total procedural cost. As procurement decisions become more evidence-based, manufacturers with strong clinical data, training ecosystems, and regulatory discipline are positioned to lead in an increasingly outcomes-focused surgical device environment.

Transformative Shifts Reshaping the Competitive Landscape

The competitive landscape is shifting from device-only selling to procedure-wide value creation. Hospitals increasingly compare anastomosis devices by consistency across surgeon skill levels, compatibility with laparoscopic and robotic workflows, and measurable contribution to enhanced recovery pathways. This is accelerating investment in powered stapling, atraumatic tissue handling, reload optimization, improved staple-line integrity, and designs that support access in narrow anatomical spaces.

Regulatory and reimbursement scrutiny is also reshaping product strategy. In the United States, FDA quality system modernization and post-market surveillance expectations are raising the bar for device reliability. In Europe, EU MDR requirements have increased clinical evidence expectations and post-market clinical follow-up obligations. Across emerging markets, local manufacturing, tender pricing, supply reliability, and surgeon education are becoming decisive factors for adoption.

Cumulative Impact of Artificial Intelligence on Anastomosis Devices

Artificial intelligence is not yet a core feature in most commercial anastomosis devices, but its cumulative impact is becoming strategically important. AI-enabled surgical video analytics, tissue perfusion assessment, robotic workflow guidance, and predictive risk models can help teams identify patients at higher risk of anastomotic leak and support more standardized intraoperative decisions. The FDA has listed hundreds of AI and machine learning-enabled medical devices, demonstrating regulatory momentum for software-driven clinical decision support.

For manufacturers, AI creates opportunities beyond the device itself. Data from surgical robotics, imaging, fluorescence angiography, and electronic health records can inform training, product design, quality monitoring, and outcome benchmarking. Leaders should treat AI as an evidence-generation layer that improves procedural consistency while maintaining clear human oversight, cybersecurity safeguards, data governance, and regulatory compliance.

Key Regional Insights Across Global Anastomosis Device Markets

North America remains a high-value region due to advanced hospital infrastructure, strong adoption of laparoscopic and robotic surgery, and established reimbursement pathways for complex gastrointestinal, bariatric, thoracic, and cardiovascular procedures. Europe is shaped by strong clinical governance and EU MDR-driven evidence requirements, with Germany, France, Italy, Spain, and the United Kingdom supporting steady demand through high surgical capacity, structured procurement, and innovation-focused health systems.

Asia-Pacific is the fastest-moving opportunity zone, supported by expanding surgical access in China, India, Japan, South Korea, Australia, and ASEAN countries, alongside rising minimally invasive surgery penetration and specialist training. Latin America, led by Brazil and Mexico, is advancing through private hospital investment and demand for minimally invasive colorectal and bariatric surgery, although pricing pressure remains material. The Middle East, particularly GCC health systems, is investing in surgical modernization, tertiary care capacity, and medical tourism, while Africa presents long-term potential as access to safe surgery, operating-room infrastructure, and specialist surgical training expand from a comparatively low base.

Key Group Insights for G7, EU, BRICS, ASEAN, GCC, and NATO Markets

The G7 anchors premium demand for advanced anastomosis devices through high procedural volumes, mature reimbursement, strong clinical training networks, and early adoption of robotic and minimally invasive surgery. The European Union emphasizes clinical evidence, post-market performance, traceability, and procurement transparency, making EU MDR readiness a competitive differentiator. NATO markets overlap significantly with advanced hospital systems that prioritize supply security, device quality, and resilient procurement for essential surgical technologies.

BRICS countries represent scale-driven growth, with China, India, and Brazil expanding surgical capacity, local manufacturing relevance, and access to advanced gastrointestinal and cardiovascular procedures. ASEAN demand is rising as Thailand, Malaysia, Singapore, Indonesia, Vietnam, and the Philippines invest in hospital modernization, medical tourism, and specialist surgical training. GCC countries are accelerating adoption through public-sector healthcare investment, tertiary hospital expansion, and preference for high-quality surgical technologies in advanced care centers.

Key Country Insights for Major Anastomosis Device Markets

The United States leads in premium adoption due to large procedure volumes, strong surgeon training networks, established reimbursement, and early uptake of robotic-assisted surgery, while Canada favors evidence-based procurement and standardized hospital purchasing. Mexico and Brazil offer regional growth through private hospital expansion and rising demand for bariatric, colorectal, and general surgery. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature surgical infrastructure with increasing pressure to prove cost-effectiveness and clinical value, while Russia remains influenced by import dependence, localization priorities, and public procurement requirements.

China and India are central to long-term volume growth as hospital capacity expands, surgical access improves, and minimally invasive surgery penetration increases. Japan and South Korea remain innovation-intensive markets with sophisticated surgical practice and high expectations for precision, safety, and product quality. Australia supports adoption through advanced tertiary care, strong regulatory oversight, and demand for clinically validated anastomosis devices in colorectal, vascular, thoracic, and general surgery.

Actionable Recommendations for Anastomosis Device Industry Leaders

Industry leaders should prioritize clinical evidence that links device performance to measurable outcomes, including leak reduction, operative efficiency, readmission avoidance, fewer complications, and surgeon usability. Product portfolios should be aligned to minimally invasive, open, and robotic procedures, with modular reloads, tissue-specific designs, ergonomic platforms, and training programs that reduce variability across hospital systems.

Manufacturers should also strengthen market access strategies with health-economic evidence, local regulatory expertise, and resilient supply chains. Partnerships with surgical training centers, robotics ecosystems, imaging specialists, and data analytics providers can improve adoption and evidence generation. In emerging markets, tiered product strategies, distributor quality controls, service support, and surgeon education will be essential to balance affordability with safety and performance.

Research Methodology and Evidence Framework

This executive summary is built on secondary and primary research principles used in medical technology market assessment. The analysis synthesizes publicly available regulatory information, hospital adoption trends, peer-reviewed surgical literature, health-system procurement behavior, medical device policy updates, and macro indicators such as surgical access, aging demographics, and minimally invasive surgery penetration.

Market interpretation emphasizes triangulation rather than reliance on a single source. Device demand is assessed through procedure relevance, regulatory readiness, clinical evidence, regional infrastructure, reimbursement maturity, surgeon training, and competitive positioning. AI impact is evaluated conservatively, focusing on validated use cases in surgical analytics, imaging, robotics, perfusion assessment, and risk prediction rather than unsupported claims of fully autonomous anastomosis.

Conclusion and Strategic Outlook

The anastomosis devices market is moving toward evidence-based, technology-enabled, and procedure-integrated solutions. Momentum is supported by the continued expansion of minimally invasive surgery, the need for consistent anastomotic outcomes, and rising demand for efficient surgical care across developed and emerging health systems.

Organizations that combine reliable engineering, clinical validation, regulatory excellence, AI-enabled insights, and practical surgeon training will be best positioned to strengthen adoption. The strongest opportunities will come from solutions that reduce variability, improve safety, support robotic workflows, and demonstrate clear value to hospitals, surgeons, payers, and patients.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anastomosis Devices Market, by Product Type

• 7.1. Stapling Devices
• 7.2. Hand-Suturing Devices
• 7.3. Sealants & Adhesives
• 7.4. Compression & Magnetic Devices

8. Anastomosis Devices Market, by Technology

• 8.1. Manual
• 8.2. Powered

9. Anastomosis Devices Market, by Procedure Type

• 9.1. Minimally Invasive
• 9.2. Open Surgery

10. Anastomosis Devices Market, by Material Type

• 10.1. Biodegradable
  • 10.1.1. Polyglycolic Acid
  • 10.1.2. Polylactic Acid
• 10.2. Composite
• 10.3. Metal
  • 10.3.1. Titanium
  • 10.3.2. Stainless Steel

11. Anastomosis Devices Market, by Usage Mode

• 11.1. Single-Use
• 11.2. Reusable

12. Anastomosis Devices Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Online Sales
• 12.3. Distributors

13. Anastomosis Devices Market, by Application

• 13.1. Cardiovascular
  • 13.1.1. Coronary
  • 13.1.2. Vascular
• 13.2. Gastrointestinal
  • 13.2.1. Colorectal
  • 13.2.2. Esophageal
  • 13.2.3. Gastric

14. Anastomosis Devices Market, by End Use

• 14.1. Ambulatory Surgical Center
• 14.2. Hospitals
• 14.3. Specialty Clinic

15. Anastomosis Devices Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Anastomosis Devices Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Anastomosis Devices Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Applied Medical Resources Corporation
• 19.3. AtriCure, Inc.
• 19.4. B. Braun Melsungen AG
• 19.5. Baxter International Inc.
• 19.6. Becton, Dickinson and Company
• 19.7. Biosintex
• 19.8. Boston Scientific Corporation
• 19.9. Cardinal Health, Inc.
• 19.10. ConMed Corporation
• 19.11. Cook Medical LLC
• 19.12. CryoLife, Inc.
• 19.13. Edwards Lifesciences Corporation
• 19.14. Getinge AB
• 19.15. Intuitive Surgical, Inc.
• 19.16. Johnson & Johnson Services, Inc.
• 19.17. LivaNova PLC
• 19.18. Medtronic Plc
• 19.19. Meril Life Sciences Pvt. Ltd.
• 19.20. Peters Surgical Company, Inc.
• 19.21. Smiths Group plc
• 19.22. Stryker Corporation
• 19.23. Teleflex Incorporated
• 19.24. Terumo Corporation
• 19.25. W. L. Gore & Associates, Inc.